Horizon scanning: Interim analysis shows improved survival with bevacizumab in recurrent and metastatic cervical cancer

Source: PharmaLive Area: News PharmaLive has reported on the results of an interim analysis of the GOG240 randomised controlled trial, which evaluated the addition of bevacizumab to chemotherapy in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment.   The study enrolled 452 patients in the US and Spain between 2009 and 2012, and was designed to address two questions: 1) is topotecan plus paclitaxel superior to cisplatin plus paclitaxel in combination and 2) does the addition of bevacizumab to either regimen improved overall survival (OS). Patients were thus randomised to one of four treatment groups, two of which received bevacizumab.   The results of an analysis previously reported in 2012 showed that topotecan plus paclitaxel was not superior to the standard therapy of cisplatin plus paclitaxel. The current interim analysis looked at the addition of bevacizumab to chemotherapy and the report states that this was associated with a ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news